Responses
Spondyloarthritis
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
Compose a Response to This Article
Other responses
No responses have been published for this article.